Hemocyte differentiation to the megacyte lineage enhances mosquito immunity against Plasmodium

  1. Ana Beatriz Ferreira Barletta
  2. Banhisikha Saha
  3. Nathanie Trisnadi
  4. Octavio Talyuli
  5. Gianmarco Raddi
  6. Carolina Barillas-Mury  Is a corresponding author
  1. National Institute of Allergy and Infectious Diseases, United States
  2. Atropos Therapeutics Inc, United States
  3. Universidade Federal Rural do Rio de Janeiro, Brazil
  4. University of Cambridge, United Kingdom

Abstract

Activation of Toll signaling in Anopheles gambiae by silencing Cactus, a suppressor of this pathway, enhances local release of hemocyte-derived microvesicles (HdMv), promoting activation of the mosquito complement-like system, which eliminates Plasmodium ookinetes. We uncovered the mechanism of this immune enhancement. Cactus silencing triggers a Rel1-mediated differentiation of granulocytes to the megacyte lineage, a new subpopulation of giant cells, resulting in a dramatic increase in the proportion of circulating megacytes. Megacytes are very plastic cells that are massively recruited to the basal midgut surface in response to Plasmodium infection. We show that Toll signaling modulates hemocyte differentiation and that megacyte recruitment to the midgut greatly enhances mosquito immunity against Plasmodium.

Data availability

Sequencing data have been deposited in ArrayExpress under this linkhttps://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-11252

The following data sets were generated

Article and author information

Author details

  1. Ana Beatriz Ferreira Barletta

    Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9913-3775
  2. Banhisikha Saha

    Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, United States
    Competing interests
    No competing interests declared.
  3. Nathanie Trisnadi

    Atropos Therapeutics Inc, San Carlos, United States
    Competing interests
    Nathanie Trisnadi, is affiliated with Atropos Therapeutics Inc.. The author has no financial interests to declare.
  4. Octavio Talyuli

    Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal Rural do Rio de Janeiro, Rio de Janeiro, Brazil
    Competing interests
    No competing interests declared.
  5. Gianmarco Raddi

    School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1056-5403
  6. Carolina Barillas-Mury

    Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, United States
    For correspondence
    cbarillas@niaid.nih.gov
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4039-6199

Funding

No external funding was received for this work

Reviewing Editor

  1. Bruno Lemaitre, École Polytechnique Fédérale de Lausanne, Switzerland

Ethics

Animal experimentation: Public Health Service Animal Welfare Assurance #A4149-01 guidelines were followed according to the National Institutes of Health Animal (NIH) Office of Animal Care and Use (OACU). These studies were done according to the NIH animal study protocol (ASP) approved by the NIH Animal Care and User Committee (ACUC), with approval ID ASP-LMVR5.

Version history

  1. Preprint posted: December 24, 2021 (view preprint)
  2. Received: June 16, 2022
  3. Accepted: September 1, 2022
  4. Accepted Manuscript published: September 2, 2022 (version 1)
  5. Version of Record published: October 6, 2022 (version 2)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,482
    views
  • 327
    downloads
  • 7
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ana Beatriz Ferreira Barletta
  2. Banhisikha Saha
  3. Nathanie Trisnadi
  4. Octavio Talyuli
  5. Gianmarco Raddi
  6. Carolina Barillas-Mury
(2022)
Hemocyte differentiation to the megacyte lineage enhances mosquito immunity against Plasmodium
eLife 11:e81116.
https://doi.org/10.7554/eLife.81116

Share this article

https://doi.org/10.7554/eLife.81116

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease
    Yi-Shin Chang, Kai Huang ... David L Perkins
    Research Article

    Background:

    End-stage renal disease (ESRD) patients experience immune compromise characterized by complex alterations of both innate and adaptive immunity, and results in higher susceptibility to infection and lower response to vaccination. This immune compromise, coupled with greater risk of exposure to infectious disease at hemodialysis (HD) centers, underscores the need for examination of the immune response to the COVID-19 mRNA-based vaccines.

    Methods:

    The immune response to the COVID-19 BNT162b2 mRNA vaccine was assessed in 20 HD patients and cohort-matched controls. RNA sequencing of peripheral blood mononuclear cells was performed longitudinally before and after each vaccination dose for a total of six time points per subject. Anti-spike antibody levels were quantified prior to the first vaccination dose (V1D0) and 7 d after the second dose (V2D7) using anti-spike IgG titers and antibody neutralization assays. Anti-spike IgG titers were additionally quantified 6 mo after initial vaccination. Clinical history and lab values in HD patients were obtained to identify predictors of vaccination response.

    Results:

    Transcriptomic analyses demonstrated differing time courses of immune responses, with prolonged myeloid cell activity in HD at 1 wk after the first vaccination dose. HD also demonstrated decreased metabolic activity and decreased antigen presentation compared to controls after the second vaccination dose. Anti-spike IgG titers and neutralizing function were substantially elevated in both controls and HD at V2D7, with a small but significant reduction in titers in HD groups (p<0.05). Anti-spike IgG remained elevated above baseline at 6 mo in both subject groups. Anti-spike IgG titers at V2D7 were highly predictive of 6-month titer levels. Transcriptomic biomarkers after the second vaccination dose and clinical biomarkers including ferritin levels were found to be predictive of antibody development.

    Conclusions:

    Overall, we demonstrate differing time courses of immune responses to the BTN162b2 mRNA COVID-19 vaccination in maintenance HD subjects comparable to healthy controls and identify transcriptomic and clinical predictors of anti-spike IgG titers in HD. Analyzing vaccination as an in vivo perturbation, our results warrant further characterization of the immune dysregulation of ESRD.

    Funding:

    F30HD102093, F30HL151182, T32HL144909, R01HL138628. This research has been funded by the University of Illinois at Chicago Center for Clinical and Translational Science (CCTS) award UL1TR002003.

    1. Microbiology and Infectious Disease
    Michael D Sacco, Lauren R Hammond ... Yu Chen
    Research Article

    In the Firmicutes phylum, GpsB is a membrane associated protein that coordinates peptidoglycan synthesis with cell growth and division. Although GpsB has been studied in several bacteria, the structure, function, and interactome of Staphylococcus aureus GpsB is largely uncharacterized. To address this knowledge gap, we solved the crystal structure of the N-terminal domain of S. aureus GpsB, which adopts an atypical, asymmetric dimer, and demonstrates major conformational flexibility that can be mapped to a hinge region formed by a three-residue insertion exclusive to Staphylococci. When this three-residue insertion is excised, its thermal stability increases, and the mutant no longer produces a previously reported lethal phenotype when overexpressed in Bacillus subtilis. In S. aureus, we show that these hinge mutants are less functional and speculate that the conformational flexibility imparted by the hinge region may serve as a dynamic switch to finetune the function of the GpsB complex and/or to promote interaction with its various partners. Furthermore, we provide the first biochemical, biophysical, and crystallographic evidence that the N-terminal domain of GpsB binds not only PBP4, but also FtsZ, through a conserved recognition motif located on their C-termini, thus coupling peptidoglycan synthesis to cell division. Taken together, the unique structure of S. aureus GpsB and its direct interaction with FtsZ/PBP4 provide deeper insight into the central role of GpsB in S. aureus cell division.